0R15 7793.0 0.1028% 0R1E 7575.0 -1.8782% 0M69 None None% 0R2V 184.5 6.0345% 0QYR 1387.5 0.7991% 0QYP 405.5 -0.7344% 0LCV 141.03 0.952% 0RUK None None% 0RYA 1733.01 -1.0839% 0RIH 165.3 0.3643% 0RIH 165.3 0.3643% 0R1O 186.6 9945.7604% 0R1O None None% 0QFP None None% 0M2Z 299.0593 0.5664% 0VSO None None% 0R1I None None% 0QZI 450.5 2.7366% 0QZ0 220.0 0.0% 0NZF None None%
Last update at 2024-02-15T18:01:45.703550Z
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Income before tax | -36.10000M | 77.60M | 74.00M | 40.90M | 27.80M |
| Minority interest | - | - | - | - | 0.00000M |
| Net income | -27.90000M | 58.20M | 55.50M | 33.90M | 30.90M |
| Selling general administrative | 359.20M | 178.60M | 151.30M | 134.90M | 125.70M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 426.30M | 384.80M | 345.90M | 291.60M | 273.10M |
| Reconciled depreciation | 89.70M | 89.10M | 15.50M | 14.20M | 9.80M |
| Ebit | 8.40M | 164.40M | 146.50M | 116.80M | 112.80M |
| Ebitda | 98.10M | 253.50M | 162.00M | 131.00M | 122.60M |
| Depreciation and amortization | 89.70M | 89.10M | 15.50M | 14.20M | 9.80M |
| Non operating income net other | - | - | - | - | - |
| Operating income | 6.30M | 95.50M | 84.00M | 52.20M | 112.80M |
| Other operating expenses | 755.20M | 511.70M | 521.00M | 456.40M | 436.30M |
| Interest expense | 43.90M | 12.20M | 9.80M | 11.50M | 10.50M |
| Tax provision | -8.20000M | 19.40M | 18.50M | 7.00M | -3.10000M |
| Interest income | 0.80M | 0.10M | 12.80M | 0.10M | 10.20M |
| Net interest income | -43.10000M | -12.10000M | -9.80000M | -11.40000M | -10.50000M |
| Extraordinary items | - | - | - | - | 10.00M |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -8.20000M | 19.40M | 18.50M | 7.00M | -3.10000M |
| Total revenue | 761.50M | 681.80M | 608.00M | 515.10M | 481.80M |
| Total operating expenses | 420.00M | 214.70M | 258.90M | 232.90M | 227.60M |
| Cost of revenue | 335.20M | 297.00M | 262.10M | 223.50M | 208.70M |
| Total other income expense net | -53.20000M | -18.20000M | -13.00000M | -17.80000M | -85.00000M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -27.90000M | 58.20M | 55.50M | 33.90M | 30.90M |
| Net income applicable to common shares | -27.90000M | 58.20M | 55.50M | 33.90M | 30.90M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Total assets | 1569.40M | 1293.30M | 1214.10M | 1237.60M | 1048.50M |
| Intangible assets | 587.90M | 485.10M | 479.70M | 438.40M | 434.90M |
| Earning assets | - | - | - | - | - |
| Other current assets | 147.80M | 147.80M | 124.30M | 100.70M | 107.80M |
| Total liab | 814.20M | 626.50M | 581.20M | 600.10M | 539.40M |
| Total stockholder equity | 755.20M | 666.80M | 632.90M | 637.50M | 509.10M |
| Deferred long term liab | 5.10M | 5.30M | 5.60M | 6.10M | 5.50M |
| Other current liab | 4.10M | 6.40M | 22.60M | 8.90M | 5.10M |
| Common stock | 1.10M | 1.10M | 1.10M | 1.10M | 1.00M |
| Capital stock | 1.10M | 1.10M | 1.10M | 1.10M | 1.00M |
| Retained earnings | 86.60M | 164.00M | 147.70M | 126.40M | 124.20M |
| Other liab | 149.60M | 142.00M | 109.90M | 112.40M | 107.40M |
| Good will | 334.50M | 245.40M | 236.10M | 253.80M | 252.10M |
| Other assets | 10.00M | 7.60M | 7.60M | 8.80M | 6.40M |
| Cash | 74.40M | 120.90M | 118.40M | 227.40M | 80.30M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 164.00M | 158.70M | 155.80M | 137.30M | 118.10M |
| Current deferred revenue | 11.50M | 12.20M | 16.60M | 25.60M | 16.30M |
| Net debt | 430.10M | 208.20M | 200.20M | 127.60M | 227.80M |
| Short term debt | 3.90M | 3.30M | 3.10M | 4.60M | 1.20M |
| Short long term debt | - | - | 0.00000M | 1.40M | 1.20M |
| Short long term debt total | 504.50M | 329.10M | 318.60M | 355.00M | 308.10M |
| Other stockholder equity | -87.70000M | -165.10000M | -148.80000M | -127.50000M | 383.90M |
| Property plant equipment | 159.30M | 100.30M | 87.00M | 76.40M | 58.40M |
| Total current assets | 467.90M | 444.40M | 392.20M | 448.90M | 292.10M |
| Long term investments | - | - | - | - | 10.10M |
| Net tangible assets | -162.10000M | -58.40000M | -77.30000M | -48.60000M | -166.00000M |
| Short term investments | - | - | - | 0.30M | 0.30M |
| Net receivables | 161.90M | 136.80M | 119.20M | 97.30M | 103.80M |
| Long term debt | 487.60M | 313.70M | 302.70M | 338.60M | 306.90M |
| Inventory | 217.30M | 175.70M | 149.50M | 120.80M | 104.00M |
| Accounts payable | 144.50M | 136.80M | 113.50M | 98.20M | 95.50M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | - | -51.40000M | -42.70000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 1.10M | 1.10M | 1.00M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 15.80M | 17.10M | 17.40M | 0.30M | 0.30M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 1101.50M | 848.90M | 821.90M | 788.70M | 756.40M |
| Capital lease obligations | 16.90M | 15.40M | 15.90M | 15.00M | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Investments | -426.20000M | -78.30000M | -0.80000M | -7.60000M | -7.60000M |
| Change to liabilities | -7.60000M | 14.90M | 20.30M | 0.10M | 6.30M |
| Total cashflows from investing activities | -426.20000M | -78.30000M | -136.10000M | -81.50000M | -61.90000M |
| Net borrowings | 186.30M | -3.60000M | -19.50000M | 22.40M | 7.30M |
| Total cash from financing activities | 316.50M | -46.10000M | -55.10000M | 118.90M | -20.10000M |
| Change to operating activities | - | - | - | - | - |
| Net income | 6.30M | 95.50M | 84.00M | 52.20M | 39.00M |
| Change in cash | -46.50000M | 2.50M | -109.00000M | 147.10M | 0.60M |
| Begin period cash flow | 120.90M | 118.40M | 227.40M | 80.30M | 79.70M |
| End period cash flow | 74.40M | 120.90M | 118.40M | 227.40M | 80.30M |
| Total cash from operating activities | 63.60M | 122.90M | 89.10M | 106.40M | 81.80M |
| Issuance of capital stock | 181.90M | 2.30M | 2.30M | 131.50M | 1.20M |
| Depreciation | 89.70M | 89.10M | 15.50M | 14.20M | 9.80M |
| Other cashflows from investing activities | 0.80M | 0.10M | -1.30000M | 0.30M | 0.30M |
| Dividends paid | 51.70M | 44.80M | 37.90M | 33.30M | 28.40M |
| Change to inventory | -31.10000M | -19.30000M | -36.60000M | -15.70000M | -14.10000M |
| Change to account receivables | -21.50000M | -23.40000M | -19.70000M | 6.90M | -11.70000M |
| Sale purchase of stock | -15.10000M | - | 13.60M | 140.20M | 1.20M |
| Other cashflows from financing activities | 368.20M | -3.60000M | -17.20000M | 152.20M | 43.90M |
| Change to netincome | 62.00M | 4.10M | -20.90000M | -2.60000M | -16.20000M |
| Capital expenditures | 30.30M | 77.60M | 134.80M | 49.20M | 22.50M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -60.20000M | -27.80000M | -36.00000M | -8.70000M | -19.50000M |
| Stock based compensation | -0.80000M | 3.30M | 2.80M | 1.50M | 2.30M |
| Other non cash items | 18.00M | 2.40M | 77.60M | 75.60M | 84.40M |
| Free cash flow | 33.30M | 45.30M | -45.70000M | 57.20M | 59.30M |
Sector: Healthcare Industry: Drug Manufacturers - General
| Company | Change (GBP) | Price (GBP) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| DPH Dechra Pharmaceuticals PLC |
- -% | - | - | 20.41 | 5.75 | 5.79 | 6.31 | 49.27 |
| AZN AstraZeneca PLC |
-106.0 0.87% | 12050.00 | 34.90 | 15.70 | 3.61 | 5.45 | 3.98 | 13.14 |
| GSK GlaxoSmithKline PLC |
5.00 0.29% | 1733.50 | 9.79 | 9.19 | 2.01 | 4.53 | 2.48 | 7.65 |
Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, internal medicine, and nutrition products supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. It also provides water soluble antibiotics, vaccines, lameness, pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. In addition, the company distributes veterinary pharmaceuticals and equipment; markets pet diets; and develops, regulates, manufactures, and markets crop protection, as well as offers financial services. It markets its products through wholesaler and distributor networks. The company operates in the United Kingdom, Germany, rest of Europe, the United States, and internationally. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.
24 Cheshire Avenue, Northwich, United Kingdom, CW9 7UA
| Name | Title | Year Born |
|---|---|---|
| Mr. Ian D. Page | CEO, MD & Exec. Director | 1961 |
| Mr. Paul Nicholas Sandland MAAT, FCCA | CFO & Exec. Director | 1979 |
| Dr. Anthony Gerard Griffin | MD of Dechra Veterinary Products for Europe & Exec. Director | 1963 |
| Mr. Patrick Meeus | Group Scientific Officer | NA |
| Ms. Katy Clough | Group HR Director | NA |
| Mr. Mike Eldred | Pres of North America | 1970 |
| Ms. Melanie Hall | Company Sec. | NA |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
UK 
AU
CA
US
NZ
Please wait processing your request...